Zhidong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhidong Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Yi Han
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
4 shared publicationsNing Xiao
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
3 shared publicationsShijie Zhou
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
3 shared publicationsDaping Yu
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
2 shared publications- Shaofa Xu
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Machang 97, Tongzhou District, Beijing, 101149, China
2 shared publications Shuku Liu
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
2 shared publications
Latest Publications
- Open Access
- 24 May 2021
- Vol. 24 (6) , 420-425
新辅助免疫治疗联合化疗在可手术的非小细胞肺癌的初步疗效评估
初步研究证实新辅助免疫联合化疗对可手术非小细胞肺癌近期疗效显著,但国内相关临床试验较少。本研究回顾性分析应用新辅助免疫治疗联合化疗的可手术Ib期-IIIb期非小细胞肺癌的临床病理资料,初步评估新辅助免疫治疗联合化疗的疗效及安全性。 回顾性分析2019年11月-2020年12月期间于首都医科大学附属北京胸科医院胸外科治疗的临床分期Ib期-IIIb期的非小细胞肺癌患者20例,术前应用免疫联合化疗新辅助治疗,根据影像学和病理学方法分别评估疗效。 全组患者新辅助治疗后影像学评估疗效,客观有效率(objective response rate, ORR)为85.0%(完全缓解4例,部分缓解13例),疾病稳定1例(5.0%),疾病进展2例(10.0%)。其中17例后续接受手术治疗,16例达到R0(no residual tumor)切除,1例R1(microscopic residual tumor)切除。术后病理评估:主要病理缓解率(major pathologic response, MPR)为47.1%(8/17),其中完全病理缓解率(complete pathologic response, CPR)为29.4%(5/17)。主要不良反应:免疫相关性肺炎(Ⅳ级)1例,Ⅲ级及以上血液学毒性9例(45.0%)。 新辅助免疫联合化疗对于可手术的非小细胞肺癌近期疗效显著,具有一定的安全性及有效性。但新辅助免疫联合化疗的远期疗效、最佳周期数以及理想预测免疫治疗效果的标记物仍有待研究。
- 24 May 2021
- Vol. 24 (6) , 420-425
Open Access新辅助免疫治疗联合化疗在可手术的非小细胞肺癌的初步疗效评估
初步研究证实新辅助免疫联合化疗对可手术非小细胞肺癌近期疗效显著,但国内相关临床试验较少。本研究回顾性分析应用新辅助免疫治疗联合化疗的可手术Ib期-IIIb期非小细胞肺癌的临床病理资料,初步评估新辅助免疫治疗联合化疗的疗效及安全性。 回顾性分析2019年11月-2020年12月期间于首都医科大学附属北京胸科医院胸外科治疗的临床分期Ib期-IIIb期的非小细胞肺癌患者20例,术前应用免疫联合化疗新辅助治疗,根据影像学和病理学方法分别评估疗效。 全组患者新辅助治疗后影像学评估疗效,客观有效率(objective response rate, ORR)为85.0%(完全缓解4例,部分缓解13例),疾病稳定1例(5.0%),疾病进展2例(10.0%)。其中17例后续接受手术治疗,16例达到R0(no residual tumor)切除,1例R1(microscopic residual tumor)切除。术后病理评估:主要病理缓解率(major pathologic response, MPR)为47.1%(8/17),其中完全病理缓解率(complete pathologic response, CPR)为29.4%(5/17)。主要不良反应:免疫相关性肺炎(Ⅳ级)1例,Ⅲ级及以上血液学毒性9例(45.0%)。 新辅助免疫联合化疗对于可手术的非小细胞肺癌近期疗效显著,具有一定的安全性及有效性。但新辅助免疫联合化疗的远期疗效、最佳周期数以及理想预测免疫治疗效果的标记物仍有待研究。
- Open Access
- 1 August 2015
- Vol. 7 (8) , 1414-1422-22
Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.
Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis
- 1 August 2015
- Vol. 7 (8) , 1414-1422-22
Open AccessRandomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.
Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis
- Open Access
- 1 September 2014
- Vol. 6 (9) , 1230-1238-1238
Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China
Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China
- 1 September 2014
- Vol. 6 (9) , 1230-1238-1238
Open AccessRisk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China
Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China
- 1 January 2014
- Vol. 127 (8) , 1464-8
Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
Personalized medicine becomes essential in lung cancer treatment, however lung-cancer-related gene expression profiles in Chinese patients remain unknown. In this study, the correlation of gene expression profiles and clinical characteristics in non-small-cell lung cancer (NSCLC) was investigated. Seventy-six Chinese patients with NSCLC were enrolled in the study to investigate mRNA expression profiles of excision repair cross complement group 1 (ERCC1), thymidylate synthetase (TYMS), ribonucleotide reductase (RRM1), class III β-tubulin (TUBB3), and epidermal growth factor receptor (EGFR) genes and their correlation with patient clinical characteristics. A novel liquidchip technology was used to detect mRNA expression levels in formalin fixed paraffin embedded tumor pathology samples. The relationships between gene expression and clinical characteristics were assessed using the Mann-Whitney test. ERCC1 mRNA levels were higher in tumors from patients with metastatic disease than patients with non-metastatic disease (P = 0.021), and higher in adenocarcinomas than squamous cell carcinomas (P = 0.006). Increased TUBB3 mRNA expression levels were found in patients with performance status (PS) 1 in comparison with PS 0 (P = 0.049), with poorly differentiated tumors in comparison with tumors that were moderately and well differentiated (P ≤ 0.000 1), and with advanced stage in comparison with early stage disease (P ≤ 0.000 1). ERCC1 mRNA levels were higher in metastatic adenocarcinoma NSCLC; TUBB3 mRNA levels were significantly higher in poorly differentiated tumors and in advanced stage NSCLC, which indicates the poor prognosis.
- 1 January 2014
- Vol. 127 (8) , 1464-8
Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
Personalized medicine becomes essential in lung cancer treatment, however lung-cancer-related gene expression profiles in Chinese patients remain unknown. In this study, the correlation of gene expression profiles and clinical characteristics in non-small-cell lung cancer (NSCLC) was investigated. Seventy-six Chinese patients with NSCLC were enrolled in the study to investigate mRNA expression profiles of excision repair cross complement group 1 (ERCC1), thymidylate synthetase (TYMS), ribonucleotide reductase (RRM1), class III β-tubulin (TUBB3), and epidermal growth factor receptor (EGFR) genes and their correlation with patient clinical characteristics. A novel liquidchip technology was used to detect mRNA expression levels in formalin fixed paraffin embedded tumor pathology samples. The relationships between gene expression and clinical characteristics were assessed using the Mann-Whitney test. ERCC1 mRNA levels were higher in tumors from patients with metastatic disease than patients with non-metastatic disease (P = 0.021), and higher in adenocarcinomas than squamous cell carcinomas (P = 0.006). Increased TUBB3 mRNA expression levels were found in patients with performance status (PS) 1 in comparison with PS 0 (P = 0.049), with poorly differentiated tumors in comparison with tumors that were moderately and well differentiated (P ≤ 0.000 1), and with advanced stage in comparison with early stage disease (P ≤ 0.000 1). ERCC1 mRNA levels were higher in metastatic adenocarcinoma NSCLC; TUBB3 mRNA levels were significantly higher in poorly differentiated tumors and in advanced stage NSCLC, which indicates the poor prognosis.
- Open Access
- 30 October 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (10) , 6061-6064
Pulmonary Lobectomy Combined with Pulmonary Arterioplasty by Complete Video-assisted Thoracic Surgery in Patients with Lung Cancer
Pulmonary Lobectomy Combined with Pulmonary Arterioplasty by Complete Video-assisted Thoracic Surgery in Patients with Lung Cancer Thoracoscopy;pulmonary arterioplasty;sleeve bronchoplasty;lung cancer; Objective: To explore the feasibility of pulmonary lobectomy combined with pulmonary arterioplasty by complete video-assisted thoracic surgery (VATS) in patients with lung cancer, and summarize its surgical methods. Materials and Methods: Twenty-one patients with lung cancer in Beijing Chest Hospital Affiliated to Capital Medical University from Feb., 2010 to Jun., 2013 were selected, males and females accounting for 15 and 6 cases, respectively. Ten underwent right upper lobectomy, 5 right lower lobectomy, 4 left upper lobectomy (in which left upper sleeve lobectomy was conducted for 2) and 2 left lower lobectomy. At the same time, local resection of pulmonary arterioplasty was performed for 12 patients, and sleeve resection of pulmonary arterioplasty for 9. Results: Twenty-one patients recovered well after surgery. Thoracic drainage tube was maintained for 3-8 days, with an average of 4.9 days, and hospital stays were 8-15 days, with an average of 11 days. There were no deaths in the perioperative period, and the complications like pulmonary embolism, bronchopleural fistula, chest infection and pulmonary atelectasis did not occur after surgery. Conclusions: Performance of pulmonary lobectomy and pulmonary arterioplasty together by complete VATS is a safe and effective surgical method, which can expand the indications of patients with lung cancer undergoing thoracoscopic pulmonary lobectomy, and make more patients profit from such minimally invasive treatment.
- 30 October 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (10) , 6061-6064
Open AccessPulmonary Lobectomy Combined with Pulmonary Arterioplasty by Complete Video-assisted Thoracic Surgery in Patients with Lung Cancer
Pulmonary Lobectomy Combined with Pulmonary Arterioplasty by Complete Video-assisted Thoracic Surgery in Patients with Lung Cancer Thoracoscopy;pulmonary arterioplasty;sleeve bronchoplasty;lung cancer; Objective: To explore the feasibility of pulmonary lobectomy combined with pulmonary arterioplasty by complete video-assisted thoracic surgery (VATS) in patients with lung cancer, and summarize its surgical methods. Materials and Methods: Twenty-one patients with lung cancer in Beijing Chest Hospital Affiliated to Capital Medical University from Feb., 2010 to Jun., 2013 were selected, males and females accounting for 15 and 6 cases, respectively. Ten underwent right upper lobectomy, 5 right lower lobectomy, 4 left upper lobectomy (in which left upper sleeve lobectomy was conducted for 2) and 2 left lower lobectomy. At the same time, local resection of pulmonary arterioplasty was performed for 12 patients, and sleeve resection of pulmonary arterioplasty for 9. Results: Twenty-one patients recovered well after surgery. Thoracic drainage tube was maintained for 3-8 days, with an average of 4.9 days, and hospital stays were 8-15 days, with an average of 11 days. There were no deaths in the perioperative period, and the complications like pulmonary embolism, bronchopleural fistula, chest infection and pulmonary atelectasis did not occur after surgery. Conclusions: Performance of pulmonary lobectomy and pulmonary arterioplasty together by complete VATS is a safe and effective surgical method, which can expand the indications of patients with lung cancer undergoing thoracoscopic pulmonary lobectomy, and make more patients profit from such minimally invasive treatment.
- Open Access
- 30 May 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (5) , 2987-2990
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer
MRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer Non-small cell lung cancer;ERCC1;BRCA1;RRM1;TYMS;TUBB3;mRNA; Background: To explore mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in tumor tissue of postoperative patients with non-small cell lung cancer (NSCLC). Materials and Methods: Sixty NSCLC patients undergoing radical operation in our hospital from Nov., 2011 to Jun., 2012 were selected. Plasmid standards of ERCC1, BRCA1, RRM1, TYMS and TUBB3 were established and standard curves were prepared by SYBR fluorescent real-time quantitative PCR analysis. Samples from tumor centers were taken to detect mRNA expression of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in cancerous tissue during operation. The total mRNA expression quantities were compared according to different clinical characteristics. Results: The total expression quantities of 5 genotypes from high to low were ERCC1>RRM1>TUBB3>TYMS>BRCA1 in turn. By pairwise comparisons, other differences showed statistical significance (pTYMS>TUBB3>TUBB3>RRM1>BRCA1 in turn. The expression quantities of BRCA1, RRM1 and TYMS in males, smokers and patients without adenocarcinoma were all significantly higher than that in females, non-smokers and patients with adenocarcinoma, and significant differences were present (p<0.05 or p<0.01). In terms of pathological staging, the expression quantities of BRCA1, RRM1 and TYMS in phases IIa~IIb and IIIa~IIIb had a tendency to be greater than in phases I and IV. Conclusions: Resistance to chemotherapy and sensitivity to targeted therapy differ among patients with NSCLC. Differences in gene expression in different individuals were also revealed. Only according to personalized detection results can individualized therapeutic regimens be worked out, which is a new direction for oncotherapy.
- 30 May 2013
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (5) , 2987-2990
Open AccessmRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer
MRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer Non-small cell lung cancer;ERCC1;BRCA1;RRM1;TYMS;TUBB3;mRNA; Background: To explore mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in tumor tissue of postoperative patients with non-small cell lung cancer (NSCLC). Materials and Methods: Sixty NSCLC patients undergoing radical operation in our hospital from Nov., 2011 to Jun., 2012 were selected. Plasmid standards of ERCC1, BRCA1, RRM1, TYMS and TUBB3 were established and standard curves were prepared by SYBR fluorescent real-time quantitative PCR analysis. Samples from tumor centers were taken to detect mRNA expression of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in cancerous tissue during operation. The total mRNA expression quantities were compared according to different clinical characteristics. Results: The total expression quantities of 5 genotypes from high to low were ERCC1>RRM1>TUBB3>TYMS>BRCA1 in turn. By pairwise comparisons, other differences showed statistical significance (pTYMS>TUBB3>TUBB3>RRM1>BRCA1 in turn. The expression quantities of BRCA1, RRM1 and TYMS in males, smokers and patients without adenocarcinoma were all significantly higher than that in females, non-smokers and patients with adenocarcinoma, and significant differences were present (p<0.05 or p<0.01). In terms of pathological staging, the expression quantities of BRCA1, RRM1 and TYMS in phases IIa~IIb and IIIa~IIIb had a tendency to be greater than in phases I and IV. Conclusions: Resistance to chemotherapy and sensitivity to targeted therapy differ among patients with NSCLC. Differences in gene expression in different individuals were also revealed. Only according to personalized detection results can individualized therapeutic regimens be worked out, which is a new direction for oncotherapy.